Midwest Annual Conference

Rosemont, IL | October 10-13, 2018

Donald E. Stephens Convention Center

Practical Guide to the Management of Atherogenic Lipids


Elevated triglyceride (TG) levels are associated with significantly increased cardiovascular mortality and morbidity. While statins remain the mainstay of dyslipidemia, a large residual risk remains in patients treated to LDL-C goals. This program will be presented by distinguished experts in the field to provide the healthcare professional managing dyslipidemia with a clinical background of the problem, methods to screen and diagnose, evidence-based strategies, and clinical treatment plans to improve outcomes of their patients.

Learning Objectives

Discuss the etiology, diagnosis (including non-HDL-C), and risk assessment of hypertriglyceridemia (HTG), and the impact of residual CVD risk that remains beyond statin therapy, including patients with HTG

Summarize the clinical and genetic evidence for the observational and causal association between elevated triglycerides (TG) / TG-rich lipoproteins and atherosclerosis

Apply evidence-based guidelines to lifestyle and therapeutic approaches for managing patients with elevated non-HDL-C and HTG

Describe the anti-atherosclerotic / anti-inflammatory properties of TG-lowering agents, with a focus on prescription omega-3 fatty acids, and biologic/clinical characteristics of EPA and DHA

Relate the current status and recommendations on omega-3 FA dietary supplementation; Increase competency to formulate an action plan for managing elevated non-HDL-C and HTG, taking into account overall therapeutic value to achieve individualized patient goals


Download a PDF of Presented Slides.



Eliot A. Brinton, MD, FAHA, FNLA

Dr Brinton received his MD degree from The University of Utah School of Medicine, and did his Internal Medicine residency at Duke University, and his Endocrinology fellowship at The University of Washington. Dr Brinton has served as President of the ...

View Full Bio

Sergio Fazio, MD, PhD

A graduate of the medical school of the University of Rome, Italy, Dr. Fazio continued at the same institution with a fellowship in Metabolic Diseases. In 1985, he undertook a Ph.D. program in Experimental Medicine at the University of Siena, Italy, ...

View Full Bio

Educational Partners

Medtelligence, LLC

Commercial Supporters

Amarin Pharma Inc.